TIBEAY BioSciences B.V.

TIBEAY BioSciences B. V. operates in the biotechnology sector, specializing in biopharmaceuticals or agro-biological products. The company was founded in 2025 by Frans van Dalen and Paul Lelieveld and is headquartered in Nijmegen, Netherlands.

In April 2026, TIBEAY BioSciences B. V. raised EUR 35 million in venture funding led Athos KG, with participation from Meneldor and Oost NL and MIG Capital. Christian Wandersee is the CEO as of May 2026.

TIBEAY BioSciences specializes in innovative biotechnological solutions, focusing on developing advanced biological products aimed at enhancing health and sustainability. The company is engaged in the research and development of biopharmaceuticals and agro-biological products designed to address significant health challenges and improve agricultural efficiency. Their products are targeted towards healthcare providers, research institutions, and agricultural enterprises across Europe and Asia, aiming to improve patient outcomes and optimize crop yields. TIBEAY BioSciences operates on a B2B revenue model, engaging in direct sales to clients such as hospitals, clinics, and agricultural distributors.

The company focuses on developing long-term relationships with strategic partners, generating revenue through volume-based pricing contracts. Their flagship products are expected to command premium pricing due to their advanced technology and effectiveness in addressing industry challenges, ensuring a sustainable revenue framework to support continuous innovation in the biotechnology sector. TIBEAY BioSciences plans to utilize April 2026 funding to enable a European multicenter Phase 3b study and prepare an application for marketing authorization with the European Medicines Agency.